Biotech in Belgium: news and updates

News and Trends 25 Aug 2016

Daratumumab could Knock Multiple Myeloma Down and Out: EMA will Judge

Multiple Myeloma is almost a death sentence: you probably won’t make it through five more years, and even if current treatments send it to remission, your chances of relapse are high. Janssen’s new drug, Darzalex (daratumumab), has shown promise to knock MM down and out for good in Phase III trails, and it now awaits […]

August 25, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 25 Aug 2016

Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis

After losing AbbVie as a partner, Galapagos has pressed on with Gilead in the development of filgotinib for rheumatoid arthritis. Phase III trials have officially begun! Galapagos is making progress as its rheumatoid arthritis drug, filgotinib, enters Phase III clinical trials. This comes after a major setback when its deal with AbbVie fell through last fall. It’s not […]

August 25, 2016 - 2 minutesmins - By Evelyn Warner

rheumatoid arthritis anti il 6r ablynx abbvie

News and Trends 9 Aug 2016

Ablynx’ Best-In-Class Antibody might not be that ‘Compelling’ to Abbvie

Ablynx has disclosed ‘compelling’ results for its Phase IIb trial in rheumatoid arthritis. But it might have a hard time compelling AbbVie to pay €68M to continue the candidate’s development, as the grass is not as green as it seems… Ablynx‘s impressive list of big Pharma collaborations could soon need an update, as its $840 partnership with […]

August 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 3 Aug 2016

UPDATED: TiGenix finishes Phase III Stem Cell therapy to treat Crohn’s disease

Belgium is a real pioneer in developing stem cell therapies. TiGenix pushes this precursor position even further by presenting good results from a Phase III of its stem cell therapy (Cx601) treating Crohn’s disease. UPDATE (article originally published on 24/8/2015): TiGenix’s Phase III results were now published in The Lancet. Julián Panés, the global coordinator […]

August 3, 2016 - 3 minutesmins - By Philip Hemme

ono pharmaceutical biotech celyad cancer nk cell therapy

News and Trends 12 Jul 2016

Unique Natural Killer T-Cell Therapy secures €282M in Japan Deal

Belgian Celyad granted an exclusive license to Osaka based ONO Pharmaceutical for the development and commercialisation of Celyad’s unique allogeneic cell therapy in Japan, Korea and Taiwan. This license agreement opens new markets to Celyad and its NKR-2 T-cell cancer immunotherapy. In addition to a deal worth up to €282M, Celyad will also receive double digit royalties based on […]

July 12, 2016 - 3 minutesmins - By Dani Bancroft

abbvie ablynx rheumatoid arthritis nanobody

News and Trends 11 Jul 2016

Nanobody Phase II Results for Arthritis: Good but not good enough?

Ablynx has shown that its candidate for Rheumatoid arthritis could work as a monotherapy, but whether they can convince AbbVie to stick to the previous $840M deal is still unclear. Ghent-based Ablynx has hooked several big Pharmas with its Nanobody platform, based on the shorter monoclonal antibodies of llamas. One of these is AbbVie (France), which is […]

July 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

tigenix takeda stem cell therapy crohns fistula

News and Trends 6 Jul 2016

Takeda snatches up Belgian Cell therapy for Crohn’s Disease

TiGenix is licensing the rights for its cell therapy which is under EMA review and is meant to treat a serious complication of Crohn’s disease. This worldwide exclusivity deal (with exception to the US) could be worth up to €380M. Back in 2009, Leuven-based TiGenix was the first to launch at cell-based product (ChondroCellect) on the European market. […]

July 6, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 6 Jul 2016

June was a Tough Month for European Biotech… #Fail

Abivax, Celyad, Circassia and Genticel – these are all European Biotechs that took a hit after failing key clinical trials in June. How are they doing now? Four different public Biotechs suffered setbacks in some of their advanced clinical trials. And, as always, the words ‘failed to meet primary endpoint‘ weren’t very popular with investors… […]

July 6, 2016 - 3 minutesmins - By Denise Neves Gameiro

biogeneration capital ventures finance money fund biotech medtech

News and Trends 5 Jul 2016

The Fund behind the ‘Biggest Private Exit Ever’ to Raise another €50M

BioGeneration Ventures has had its first close of a new venture capital fund, ‘BioGeneration Capital Fund III’, for novel diagnostic, medtech and therapeutic biotechs in Europe. BioGeneration Ventures (BGV) is based in Naarden (Netherlands) and manages funds investing in Netherlands, Belgium and Germany. Some of its biotech porfolio companies have included Dezima Pharma (acquired by Amgen from […]

July 5, 2016 - 2 minutesmins - By Dani Bancroft

celyad c cure chart1 ischemic heart failure

News and Trends 29 Jun 2016

Cell Therapy for Heart Failure fails in Phase III … but not Entirely

Celyad failed to get significant results in its Phase III trial in cardiac disease. However, this cell therapy could still have a positive effect in a part of the patients. True potential or public relations patch? Cardiovascular diseases are the leading cause of death worldwide. Biotech solutions in the field range from gene therapy (with uniQure and […]

June 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

biotech of the week volitionrx belgium 1213x418

News and Trends 24 Jun 2016

Cost-effective diagnostics for cancer? Only with VolitionRx!

Aberdeen, we say goodbye to you! We’re leaving Scotland this week and are heading down to Belgium. Besides being the place where most of the European Union action happens, Belgium also has a strong and interesting biotech scene. That’s why in Namur we’re visiting VolitionRx, our Biotech of the Week. City: Namur (Belgium) Founded: 2010 Employees: 11-50 employees […]

June 24, 2016 - 1 minutemin - By Joachim Eeckhout

car t cancer immunooncology biotech labiotech refresh georges rawadi

News and Trends 6 Jun 2016

CAR-T: “This is totally different from what everyone else is doing”

And on the topic of CAR-T, Joachim spoke to Georges Rawadi from the Belgium based biotech, Celyad. Having originally been built on research into a cell therapy for cardiology, Celyad started back in 2007. Now Rawadi explained it’s coming to the end of a cycle for the Cardiology programme. So naturally, they asked what next? Well – […]

June 6, 2016 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Belgium

Daratumumab could Knock Multiple Myeloma Down and Out: EMA will Judge

Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis

Ablynx’ Best-In-Class Antibody might not be that ‘Compelling’ to Abbvie

UPDATED: TiGenix finishes Phase III Stem Cell therapy to treat Crohn’s disease

Unique Natural Killer T-Cell Therapy secures €282M in Japan Deal

Nanobody Phase II Results for Arthritis: Good but not good enough?

Takeda snatches up Belgian Cell therapy for Crohn’s Disease

June was a Tough Month for European Biotech… #Fail

The Fund behind the ‘Biggest Private Exit Ever’ to Raise another €50M

Cell Therapy for Heart Failure fails in Phase III … but not Entirely

Cost-effective diagnostics for cancer? Only with VolitionRx!

CAR-T: “This is totally different from what everyone else is doing”

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!